1. Филатов А. Г., Тарашвили Э. Г. Эпидемиология и социальная значимость фибрилляции предсердий. Анналы аритмологии. 2012;9:2:5-13.
2. Рубаненко О. А., Фатен-ков О. В., Хохлунов С. М. Роль факторов воспаления в развитии фибрилляции предсердий. Кардиология: Новости. Мнения. Обучение. 2015;2(5):43-7
3. Marcelle DS, Alexander HM, et al. Role of inflammation in early atrial fibrillation recurrence. EP Europace. 2012;14:810-17 doi:10.1093/europace/eur402.
4. Гареев И. Ф., Бейлерли О. А. Циркулирующие микроРНК как биомаркеры: какие перспективы? Профилактическая медицина. 2018;21 (6): 142-50. doi: 10.17116/profmed201821061142.
5. Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ Res. 2016;118(4):703-20. doi:10.1161/CIRCRESAHA.115.306300.
6. Li Y, Tan W, Ye F, et al. Identification of microRNAs and genes as biomarkers of atrial fibrillation using a bioinformatics approach. J Intern Med Res. 2019;47(8):3580-9. doi:10.1177/0300060519852235.
7. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467 doi:10.1038/nrclinonc.2011.76.
8. Bronze-da-Rocha E. MicroRNAs Expression Profiles in Cardiovascular Diseases. Biomed Res Int. 2014;2014:985408. doi:10.1155/2014/985408.
9. Romaine SP, Tomaszewski M, Condorelli G, et al. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 2015;101(12):921-8. doi:10.1136/heartjnl-2013-305402.
10. Navickas R, Gal D, Laucevicius A, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016; 1 11(4):322-37 doi:10.1093/cvr/cvw174.
11. Zhou SS, Jin JP, Wang JQ, et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets, and challenges. Acta Pharmacol Sin. 2018;39(7):1073-84. doi:10.1038/aps.2018.30.
12. Wei Z, Bing Z, Shaohuan Q, et al. Expression of miRNAs in plasma exosomes derived from patients with atrial fibrillation. Clin Cardiol. 2020; 43(12):1450-9. doi: 10.1002/clc.23461.
13. Silva AM, Araujo JN, Freitas RC, et al. Circulating MicroRNAs as potential biomarkers of atrial fibrillation. BioMed Res Int. 2017; 2017 doi:10.1155/2017/7804763.
14. Felekkis K, Papaneophytou C. Challenges in using circulating micro-RNAs as biomarkers for cardiovascular diseases. Int J Mol Sci. 2020;21(2):561. doi:10.3390/ijms21020561.
15. Appierto V, Callari M, Cavadini E, et al. A lipemia-independent NanoDrop®-based score to identify hemolysis in plasma and serum samples. Bioanalysis. 2014;6(9):1215-26. doi: 10.4155/bio.13.344.
16. Blondal T, Nielsen SJ, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59(1 ):S1-6. doi:10.1016/j.ymeth.2012.09.015.
17. Ромакина В. В., Жиров И. В., Насонова С. Н. и др. МикроРНК как биомаркеры сердечнососудистых заболеваний. Кардиология. 2018;58(1):66-71. doi:10.18087/cardio.2018.1.10083.
18. Kim GH. MicroRNA regulation of cardiac conduction and arrhythmias. Transl Res. 2013; 161 (5):381-92. doi: 10.1016/j.trsl.2012.12.004.
19. Kaur A, Mackin ST, Schlosser K, et al. Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovasc Res. 2020;116(6):1113-24. doi:10.1093/cvr/cvz302.
20. Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 2013;15(12):372. doi:10.1007/s11883-013-0372-2.
21. Jin H, Li DY, Chernogubova E, et al. Local delivery of miR-21 stabilizes fibrous caps in vulnerable atherosclerotic lesions. Mol Ther. 2018;26(4):1040-55. doi: 10.1016/j.ymthe.2018.01.011.
22. Chen C, Wang Y, Yang S, et al. MiR-320a contributes to atherogenesis by augmenting multiple risk factors and downregulating SRF. J Cell Mol Med. 2015;19(5):970-85. doi:10.1111/jcmm.12483.
23. Neth P, Nazari-Jahantigh M, Schober A, et al. MicroRNAs in flow-dependent vascular remodelling. Cardiovasc Res 2013;99(2):294-303. doi:10.1093/cvr/cvt096.
24. Stather PW, Sylvius N, Wild JB, et al. Differential MicroRNA Expression Profiles in Peripheral Arterial Disease. Circ Cardiovasc Genet. 2013;6(5):490-7 doi:10.1161/CIRCGENETICS.111.000053.
25. Jiang Y, Wang HY, Li Y, et al. Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci Rep. 2014;4:5026. doi:10.1038/srep05026.
26. Ибрагимова А. Г., Шахмаева Е. Р., Станишевская И. Е. и др. Потенциальная роль микроРНК при кальцинозе сосудов. Российский кардиологический журнал. 2019;(10):118-25. doi:10.15829/1560-4071-2019-10-118-125.
27. Boriani G, Diemberger I, Martignani C, et al. The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. Eur Heart J. 2006;27(8):893-4. doi: 10.1093/eurheartj/ehi651.